Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.

MLA

Färkkilä, Anniina, et al. “Immunogenomic Profiling Determines Responses to Combined PARP and PD-1 Inhibition in Ovarian Cancer.” Nature Communications, vol. 11, no. 1, Mar. 2020, pp. 1–13. EBSCOhost, https://doi.org/10.1038/s41467-020-15315-8.

APA

Färkkilä, A., Gulhan, D. C., Casado, J., Jacobson, C. A., Nguyen, H., Kochupurakkal, B., Maliga, Z., Yapp, C., Chen, Y.-A., Schapiro, D., Zhou, Y., Graham, J. R., Dezube, B. J., Munster, P., Santagata, S., Garcia, E., Rodig, S., Lako, A., Chowdhury, D., & Shapiro, G. I. (2020). Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature Communications, 11(1), 1–13. https://doi.org/10.1038/s41467-020-15315-8

Chicago

Färkkilä, Anniina, Doga C. Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, et al. 2020. “Immunogenomic Profiling Determines Responses to Combined PARP and PD-1 Inhibition in Ovarian Cancer.” Nature Communications 11 (1): 1–13. doi:10.1038/s41467-020-15315-8.